Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6OZQV)

Drug Name

Daclizumab Drug Info

Synonyms

DAC HYP; Daclizumab HYP; Daclizumab High Yield Process; Daclizumab (subcutaneous, multiple sclerosis); Daclizumab (subcutaneous, multiple sclerosis), Abbott/Biogen Idec

Indication

Disease Entry	ICD 11	Status	REF
Aplastic anemia	3A70	Approved	[1]
Kidney transplant rejection	NE84	Approved	[2]
Multiple sclerosis	8A40	Approved	[3]

Cross-matching ID

TTD Drug ID: DM6OZQV

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldesleukin	DM4YMIS	Acute myelogenous leukaemia	2A41	Approved	[4]
AIR-insulin	DM8SYTE	Diabetic complication	5A2Y	Phase 3	[5]
TG-4010	DMWE3GB	Bipolar disorder	6A60	Phase 2/3	[6]
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[7]
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[8]
Carboxyamidotriazole orotate	DMN5JCX	Glioblastoma multiforme	2A00.0	Phase 2	[9]
Leuvectin	DM5LQEI	Melanoma	2C30	Phase 2	[10]
Human interleukin-2	DM0NJWG	Renal cell carcinoma	2C90	Phase 2	[11]
L19-IL-2 fusion protein	DMI2XP1	Lymphoma	2A80-2A86	Phase 2	[12]
Thymoctonan	DM4BLJM	Immune System disease	4A01-4B41	Phase 2	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

References

1	Recent developments in drug therapy for aplastic anemia. Ann Pharmacother. 2014 Nov;48(11):1469-78.
2	Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75.
3	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
6	A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
7	Clinical pipeline report, company report or official report of Bioniz Therapeutics.
8	Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
9	J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
10	Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
11	Clinical pipeline report, company report or official report of Immunservice.
12	National Cancer Institute Drug Dictionary (drug id 665656).
13	Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7.